Olema Pharmaceuticals (OLMA) Price & Analysis

Compare

899 Followers

OLMA Stock Chart & Stats

$28.18

$0.55(10.50%)

At close: Jan 08 4:00 PM EST

$28.18

$0.55(10.50%)

Day’s Range― - ―

52-Week Range$2.86 - $29.51

Previous CloseN/A

Volume1.27M

Average Volume (3M)5.56M

Market Cap

$2.20B

Enterprise Value$514.84M

Total Cash (Recent Filing)$328.96M

Total Debt (Recent Filing)$4.48M

Price to Earnings (P/E)―

Beta0.83

Next Earnings

Mar 02, 2026

EPS Estimate

-0.52

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.49

Shares Outstanding78,659,920

10 Day Avg. Volume13,976,451

30 Day Avg. Volume5,560,930

Financial Highlights & Ratios

PEG Ratio-0.94

Price to Book (P/B)0.84

Price to Sales (P/S)0.00

P/FCF Ratio-3.28

Enterprise Value/Market Cap0.23

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-4.02K

Enterprise Value/Ebitda-3.19

Forecast

1Y Price Target

$41.86

Price Target Upside48.55% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessRoche's positive lidERA trial results increase confidence in the potential of Olema's palazestrant in combination with ribociclib for metastatic breast cancer.

Earnings PotentialA 90% expected share price return contributes to a positive outlook for OLMA.

Market OpportunityThe analyst recommends pursuing the adjuvant setting, which represents a materially expanded opportunity for pala, contingent on additional funding and likely a pharma partner given the size of the adjuvant market.

Bears Say

Financial StabilityOlema has a relatively high annualized cash burn rate, which may impact its financial stability.

Investment RiskThe Buy/High Risk rating indicates potential volatility and risk associated with investing in OLMA.

Investor SentimentThere is a significant short interest percentage in Olema's stock, indicating skepticism from some investors.

Olema Pharmaceuticals News

Olema Oncology rises 6.2%

Olema Oncology (OLMA) is up 6.2%, or $2.06 to $35.11. Published first on TheFly – the ultimate source...

8d ago

OLMA

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Direxion Daily S&P Bear...

11d ago

BRR

Citi more than doubles Olema target, opens ‘upside catalyst watch’

Citi raised the firm’s price target on Olema Oncology (OLMA) to $60 from $21 and keeps a Buy...

11d ago

OLMA

Olema Oncology files automatic mixed securities shelf

16:49 EST Olema Oncology (OLMA) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

12d ago

OLMA

Olema Oncology price target raised to $48 from $45 at Oppenheimer

Oppenheimer raised the firm’s price target on Olema Oncology (OLMA) to $48 from $45 and keeps an Outperform...

12d ago

CHRO

OLMA

Olema Oncology price target raised to $38 from $26 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Olema Oncology (OLMA) to $38 from $26 and keeps a...

12d ago

OLMA

Olema Oncology price target raised to $43 from $30 at Jefferies

Jefferies analyst Michael Yee raised the firm’s price target on Olema Oncology (OLMA) to $43 from $30 and...

13d ago

CHRO

OLMA

Olema Oncology rises 11.7%

Olema Oncology (OLMA) is up 11.7%, or $3.10 to $29.68. Published first on TheFly – the ultimate source...

13d ago

OLMA

Promising Potential of Olema Pharmaceuticals’ Palazestrant in Transforming ER+/HER2- Breast Cancer Treatment

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Olema Pharmaceuticals today and set a price target...

12d ago

OLMA

Positive Outlook for Olema’s OPERA-02 Trial Based on Roche’s Promising Giredestrant Data

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Olema Pharmaceuticals and keeping the price target...

13d ago

OLMA

Buy Rating for Olema Pharmaceuticals Driven by Promising Oral SERD Potential in Breast Cancer Treatment

Jefferies analyst Clara Dong maintained a Buy rating on Olema Pharmaceuticals today and set a price target of...

13d ago

OLMA

Olema Oncology price target raised to $26 from $18 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Olema Oncology (OLMA) to $26 from $18 and keeps a...

1M ago

OLMA

Midday Fly By: Nvidia reports Q3 beat, Abbott buys Exact Sciences

The major averages were broadly higher near noon, reflecting investor confidence after a strong report and guidance from...

1M ago

Olema Pharmaceuticals Announces Public Stock Offering

Olema Pharmaceuticals ( ($OLMA) ) just unveiled an announcement. On November 18, 2025, Olema Pharmaceuticals announced a public...

1M ago

OLMA

OLMA FAQ

What was Olema Pharmaceuticals’s price range in the past 12 months?

Olema Pharmaceuticals lowest stock price was $2.86 and its highest was $29.51 in the past 12 months.

What is Olema Pharmaceuticals’s market cap?

Olema Pharmaceuticals’s market cap is $2.20B.

When is Olema Pharmaceuticals’s upcoming earnings report date?

Olema Pharmaceuticals’s upcoming earnings report date is Mar 02, 2026 which is in 69 days.

How were Olema Pharmaceuticals’s earnings last quarter?

Olema Pharmaceuticals released its earnings results on Nov 11, 2025. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.475 by -$0.015.

Is Olema Pharmaceuticals overvalued?

According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Olema Pharmaceuticals pay dividends?

Olema Pharmaceuticals does not currently pay dividends.

What is Olema Pharmaceuticals’s EPS estimate?

Olema Pharmaceuticals’s EPS estimate is -0.52.

How many shares outstanding does Olema Pharmaceuticals have?

Olema Pharmaceuticals has 78,659,920 shares outstanding.

What happened to Olema Pharmaceuticals’s price movement after its last earnings report?

Olema Pharmaceuticals reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.475. Following the earnings report the stock price went down -5.862%.

Which hedge fund is a major shareholder of Olema Pharmaceuticals?

Currently, no hedge funds are holding shares in OLMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Olema Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-59.22%

Trailing 12-Months

Asset Growth

53.13%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Olema Pharmaceuticals

Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women's cancers. The company's primary focus is on the discovery and development of therapies for hormone receptor-positive breast cancer. Olema's lead product candidate, OP-1250, is designed to be a potential best-in-class complete estrogen receptor antagonist (CERAN) that inhibits estrogen receptor-positive (ER+) cancer growth.

Olema Pharmaceuticals (OLMA) Earnings & Revenues

Historic Earnings Reports

OLMA Stock 12 Month Forecast

Average Price Target

$41.86

▲(48.55% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","61":"$61","16.75":"$16.75","31.5":"$31.5","46.25":"$46.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,16.75,31.5,46.25,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.95,30.415384615384614,32.88076923076923,35.34615384615385,37.81153846153846,40.276923076923076,42.74230769230769,45.207692307692305,47.67307692307692,50.138461538461534,52.60384615384615,55.069230769230764,57.53461538461538,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.95,29.02,30.09,31.16,32.23,33.3,34.37,35.44,36.51,37.58,38.65,39.72,40.79,{"y":41.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.95,27.338461538461537,26.726923076923075,26.115384615384613,25.503846153846155,24.892307692307693,24.28076923076923,23.66923076923077,23.057692307692307,22.446153846153848,21.834615384615383,21.223076923076924,20.611538461538462,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.62,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.11,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.29,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.97,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >